Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
OBJECTIVE: Compare the efficacy and safety of monotherapy with dulaglutide, a once-weekly GLP-1 receptor agonist, to metformin-treated patients with type 2 diabetes. The primary objective compared dulaglutide 1.5 mg and metformin on change from baseline glycosylated hemoglobin A1c (HbA1c) at 26 weeks. RESEARCH DESIGN AND METHODS: This 52-week double-blind study randomized patients to subcutaneous dulaglutide 1.5 mg, dulaglutide 0.75 mg, or metformin. Patients (N = 807) had HbA1c ≥6.5% (≥48 mmol/mol) and ≤9.5% (≤80 mmol/mol) with diet and exercise alone or low-dose oral antihyperglycemic medication (OAM) monotherapy; OAMs were discontinued at beginning of lead-in period. RESULTS: At 26 weeks, changes from baseline HbA1c (least squares [LS] mean ± SE) were: dulaglutide 1.5 mg, −0.78 ± 0.06% (−8.5 ± 0.70 mmol/mol); dulaglutide 0.75 mg, −0.71 ± 0.06% (−7.8 ± 0.70 mmol/mol); and metformin, −0.56 ± 0.06% (−6.1 ± 0.70 mmol/mol). Dulaglutide 1.5 and 0.75 mg were superior to metformin (LS mean difference): −0.22% (−2.4 mmol/mol) and −0.15% (−1.6 mmol/mol) (one-sided P < 0.025, both comparisons), respectively. Greater percentages reached HbA1c targets <7.0% (<53 mmol/mol) and ≤6.5% (≤48 mmol/mol) with dulaglutide 1.5 and 0.75 mg compared with metformin (P < 0.05, all comparisons). No severe hypoglycemia was reported. Compared with metformin, decrease in weight was similar with dulaglutide 1.5 mg and smaller with dulaglutide 0.75 mg. Over 52 weeks, nausea, diarrhea, and vomiting were the most common adverse events; incidences were similar between dulaglutide and metformin. CONCLUSIONS: Dulaglutide improves glycemic control and is well tolerated as monotherapy in patients with early stage type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, the 1-year efficacy can be predicted based on early response to weight loss.761”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [761]
In the citing paper
“In these studies, mean weight change ranged from −1.0 kg to −3.78 kg over 6–12 months.”
From Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK (2022) · cites this paper as [19]
In the citing paper
“At 26 weeks after treatment, the weight loss was -2.29 ± 0.24 kg for 1.5 mg DUL, -1.36 ± 0.24 kg for 0.75 mg DUL, and -2.22 ± 0.24 kg for metformin (110).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [110]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 39 · Cited by 341
Research works printed but not linked: 2
- Gedulin, 1999, Exendin-4 (AC2993) decreases glucagon secretion during hyperglycemia clamps in diabetic fatty Zucker rats, Diabetes, 48, A199
- Jodka, 1998, Exendin-4 potently regulates gastric emptying in rats, Diabetes, 47, 1543
Metadata
- Authors
- Umpierrez, G., Tofé Povedano, S., Pérez Manghi, F., Shurzinske, L., & Pechtner, V.
- Affiliations
- Emory University (US)
- Endocrinología, Clínica Juaneda, Palma de Mallorca, Spain
- Centro de Investigaciones Metabólicas, Buenos Aires, Argentina
- Eli Lilly (United States) (US)
- Lilly Diabetes, Eli Lilly and Company, Neuilly-sur-Seine Cedex, France
- Corresponding author
- Pechtner, Valeria
- ORCID
- Umpierrez, Guillermo
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-07-12
- Volume
- 37
- Issue
- 8
- Pages
- 2168-2176
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2030546890
- Cited by
- 341
- References
- 39
- Citations by year
- 2026: 19 · 2025: 34 · 2024: 21 · 2023: 29 · 2022: 16 · 2021: 17 · 2020: 27 · 2019: 23 · 2018: 37 · 2017: 26 · 2016: 40 · 2015: 41 · 2014: 11
- FWCI
- 31.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- dulaglutide, metformin, type 2 diabetes, GLP-1 receptor agonists, monotherapy, glycemic control, HbA1c, dose comparison, weight loss, hypoglycemia, low-dose metformin, low-dose insulin
- MeSH terms
- Adult, Aged, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Metformin, Middle Aged, Recombinant Fusion Proteins, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3). https://app.cochat.ai/papers/10.2337/dc13-2759
- The paper
- Umpierrez, G., Tofé Povedano, S., Pérez Manghi, F., Shurzinske, L., & Pechtner, V. (2014). Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3). Diabetes Care. https://doi.org/10.2337/dc13-2759
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.